Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q2 2018 call → NOThe question asks whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is already visible. I need to look for a specific, identifiable piece of the company that has been proven out in real operation, and that the company is right now standing up further instances of that same piece in other locations, customers, markets, channels, applications, or lines, where management can already point to demand or commitment waiting for those new instances. Let me scan the transcript for any such description. The transcript is about Alnylam Pharmaceuticals, a biotech company. The call discusses: - ONPATTRO (patisiran) approval and launch readiness - Pipeline programs (givosiran, lumasiran, TTRsc02, etc.) - Commercial readiness efforts - Financial results The question is about "copying a part of its own business that is already working into additional places where the same demand is already visible." This sounds like a replication of a proven business unit - like opening new stores, new facilities, new markets, etc. Let me look for anything like that in the transcript. The company is preparing for the launch of ONPATTRO. They mention: - "We're launch-ready here in the U.S. and also in Germany, where we expect our first EU launch." - "we've been building a highly experienced team in Japan and we plan to follow in other countries as well building a global commercialization effort." This is about launching a product in new markets. But is this "copying a part of its own business that is already working"? The product hasn't been launched yet - it's pending approval. The PDUFA date is next week. So the product is not yet proven in real operation - it's about to be approved. Let me check the criteria: (1) A PROVEN INSTANCE THAT ALREADY WORKS - management points to something concrete that has demonstrably performed in real operation. The product ONPATTRO is not yet approved or launched. The CHMP recommended approval, but the product hasn't been sold yet. So there's no proven instance with actual customers, orders, volumes, etc. (2) COPIES ARE PHYSICALLY BEING STOOD UP NOW - they are planning launches in Germany, Japan, etc., but these are future launches, not yet physically stood up.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.